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Introduction: Bepridil is eﬀective for atrial ﬁbrillation (AF), but it can induce torsades de
pointes. Thus we examined the eﬃcacy and safety of bepridil when started at 100mg/day for
AF after failed electrical cardioversion (EC).
Methods and Results: We studied 28 consecutive patients (58 12 years old) with failed
EC. After administration of bepridil, we examined the time to restore the sinus rhythm, the
duration of the maintained sinus rhythm. Our patients were divided into the two groups and
various clinical factors were compared, including medication and echocardiographic and
electrocardiographic parameters: the SR group who maintained sinus rhythm during follow-
up period and the AF group who still had AF. Sixteen patients (57%) could maintain sinus
rhythm (SR group). Adverse arrhythmic events were not observed. There were no signiﬁcant
diﬀerences in any clinical factors between the two groups before and after bepridil.
Conclusions: Bepridil was eﬀective and safe for persistent AF with failed EC.
(J Arrhythmia 2011; 27: 131–136)
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Introduction
Atrial ﬁbrillation (AF) is the most frequent
arrhythmia observed in medical practice,1–3) and
the prevalence of AF increases with age. Superiority
of rhythm control to rate control for treatment of AF
is not established,4–6) however in certain patients
including younger patients and patients with severe
symptoms, there is an actual need to maintain sinus
rhythm.7,8) However, if we select the rhythm control-
therapy for AF including antiarrhythmic agents
and/or electrical cardioversion (EC), it is frequently
diﬃcult to restore sinus rhythm and maintain sinus
rhythm for the long term. Bepridil is an antiarrhyth-
mic agent that inhibits several ion channels including
the sodium channel, potassium channel and calcium
channel.9–12) Recently, it has been reported that
bepridil could restore the sinus rhythm in patients
with persistent atrial ﬁbrillation.13,14) However, even
in doses of 200mg/day, bepridil prolongs the QT
interval and induces torsades de pointes, which
can develop into severe ventricular tachycardia, by
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inhibiting some potassium channels.15) In this study,
we examined the eﬃcacy and safety of bepridil,
especially 100mg/day-bepridil for AF after failed
EC, and we evaluated the diﬀerences in various
clinical factors including medication and echocar-
diographic and electrocardiographic parameters be-
tween patients who maintained sinus rhythm and
those who remained in AF or relapsed into AF from
sinus rhythm.
Methods
Study patients
Between June 2005 and July 2007, we attempted
EC in a relatively young set of 44 patients (age < 65
years old) with non-valvular persistent AF (> 2
months). Among the 44 patients, 16 patients could
recover sinus rhythm by EC and be maintained using
antiarrhythmic agents other than bepridil. In this
study, we investigated the remaining 28 patients (22
male; mean age: 58 12 years old) with persistent
AF who failed to restore sinus rhythm after EC and
took bepridil at 100mg/day. The duration of AF
was determined by electrocardiogram and from the
patient reports. Patients with valvular AF, congestive
heart failure, left ventricular dysfunction (ejection
fraction < 45%), or who had an implanted pacing
device were excluded from this study. All patients
underwent echocardiography, 24-hour Holter ECG
and blood examination. Anticoagulation therapy
using warfarin was performed in all patients between
an international normalized ratio of 2.0 and 3.0 for at
least 3 weeks before EC.16,17) After admission, all
patients underwent transesophageal echocardiogra-
phy to check for a thrombus in the left atrium.18)
The protocol of the EC was as follows; shock
was delivered with external paddles positioned in
the anterior-apex position connected to an external
electrical cardioverter for biphasic external cardio-
version. A ﬁrst shock was delivered at an energy of
200 joules. If the ﬁrst shock attempt failed to convert
to sinus rhythm, a second shock was delivered at 300
joules. The next shock was delivered at 360 joules. If
cardioversion was unsuccessful at 360 joules, intra-
venous antiarrhythmic agents, either disopyramide
or pilsicainide, were added and a ﬁnal cardioversion
was attempted at 360 joules. We divided the study
patients into the following two groups and compared
the various factors including QT and QTc: SR group
who restored sinus rhythm and maintained sinus
rhythm by taking bepridil and AF group who
relapsed into AF after once restored sinus rhythm
or had never restored sinus rhythm by taking
bepridil.
The ethics committee at Osaka Rosai Hospital
approved this study, and written informed consent
was obtained from all patients before echocardio-
graphic examinations.
Administration of bepridil
After cessation of all oral antiarrhythmic agents,
bepridil was given at an initial dose of 100mg/day
for 3 months, with titration to 150–200mg/day if
100mg/day-bepridil failed to restore sinus rhythm.
Bepridil was continued for at least 12 months even if
the sinus rhythm was not recovered. Bepridil was
discontinued if severe side eﬀects including torsades
de pointes occurred.
Electrocardiographic parameters
Serial electrocardiograms were recorded at
each visit (once a month) to determine whether
the patient had converted to a sinus rhythm or
remained with AF, and we documented all instances
when the patients complained of palpitation. The
12-lead electrocardiogram was recorded at a paper
speed of 25mm/s and a gain of 10mm/mV. The
following electrocardiographic parameters were
measured just before and 12 months after admin-
istration of bepridil; QRS duration, RR interval, QT
interval and QTc interval. The QT interval was
manually measured from the lead with the longest
interval, using hand-held calipers to the nearest
10ms from the beginning of the QRS complex to the
end of the T-wave. The end of the T-wave was
deﬁned as the intersection between the tangent to
the down-sloping T wave and PR baseline. The
heart rate-corrected QT interval (QTc) was deter-
mined by dividing the QT interval by the square
root of the preceding RR interval that showed the
smallest diﬀerence between the average values of
RR intervals. If the electrocardiogram of the patients
showed AF, we used the averaged value of ten
continuous beats according to the above-mentioned
electrocardiographic parameters. In each patient, the
serial electrocardiographic parameters were meas-
ured at the same lead. We deﬁned each parameter
just before bepridil as pre each parameter (e.g.
pre QT), deﬁned each parameter 12 months after
bepridil as post parameter (e.g. post QT), and
deﬁned diﬀerence in each parameter over 12 months
as a  value for each parameter (e.g. QT = post
QT  pre QT). In the presence of persistent AF,
each electrocardiographic parameter was calculated
as the average value of ten serial ten cardiac cycles.
We compared the above-mentioned electrocardio-
graphic parameters between the SR group and the
AF group.
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Statistical analysis
Data are presented as means SD for continuous
variables. Continuous variables were compared us-
ing Student’s t-test, and categorical variables were
compared using Fisher’s exact test. A two-sided
P-value of < 0:05 was considered statistically sig-
niﬁcant. Analysis was performed using Statview 5.0
(SAS Institute Inc., Cary, North Carolina, USA).
Results
Among the 28 patients, 19 patients (68%) recov-
ered sinus rhythm once. The average time taken to
restore sinus rhythm was 2:0 2:3 months (range;
0.3–10 months). The average duration for maintain-
ing the sinus rhythm period was 17 10 months
(range; 1–40 months). Sixteen patients (57%) main-
tained sinus rhythm during the follow-up period.
Therefore, the SR group consisted of these 16
patients. In the SR group, 14 patients (88%) received
100mg/day-bepridil, one patient received 150mg
and the other received 200mg (average dosage:
109 27mg). The AF group consisted of the
remaining 3 patients, who relapsed to AF, and the
9 patients who had never restored to sinus rhythm.
All patients in the AF group received 200mg/day-
bepridil. Clinical and echocardiographic ﬁndings
of each group before starting bepridil are shown
in Table 1. A representative case of the SR group
is shown in a Figure 1. Various electrocardiographic
parameters between SR and AF groups are shown in
Table 2. There were no signiﬁcant diﬀerences in all
the electrocardiographic parameters between the two
groups (Table 2).
During the follow-up period, two adverse events
associated with bepridil occurred. One was sinus
bradycardia (33 bpm). The patient had taken 100
mg/day-bepridil for 3 months, but sinus rhythm was
not restored. Then, when the dosage was increased
to 150mg/day, sinus bradycardia appeared 1 month
later. The other event was a remarkable prolongation
of QTc (571msec). Discontinuation of bepridil
prevented these patients from suﬀering subsequent
arrhythmic events. Ventricular arrhythmias, such as
torsades de pointes or sudden cardiac death, did not
occur in the study patients.
Table 1 Diﬀerences in patient characteristics between SR and AF groups
SR group (n ¼ 16) AF group (n ¼ 12) P-value
Age (y) 61.7  11.3 54.4  11.3 0.11
Sex (male/female) 11/5 11/1 0.20
BSA(m2) 1.78  0.25 1.89  0.20 0.24
Duration of AF (months) 20.5  33.2 (2-84) 17.2  22.2 (3-70) 0.77
SBP (mmHg) 131.5  14.4 132.0  17.6 0.94
DBP (mmHg) 78.8  12.2 78.7  11.6 0.99
HR (bpm) 90.4  13.9 89.1  15.9 0.83
Hypertension (n, %) 7 (44) 6 (50) 0.99
Diabetes (n, %) 2 (13) 1 (8) 0.99
Drugs
 blocker (n, %) 7 (44) 4 (33) 0.70
Ca antagonist (n, %) 2 (13) 2 (17) 0.99
Digoxin (n, %) 1 (6) 3 (25) 0.29
None/class Ia/class Ic (n, %) 8 (50)/2(13)/6 (37) 3 (25)/5(42)/4 (33) 0.35
Echocardiographic parameters
Dd (mm) 49.9  6.9 51.7  4.5 0.46
EF (%) 66.1  10.6 61.8  6.0 0.22
LA (mm) 47.3  6.8 (41-57) 48.0  8.1 (38-60) 0.81
Mitral valve regurgitation
1.0  0.6 1.0  0.9 0.99(0, 1, 2, 3)
Tricuspid valve regurgitation
1.0  0.7 1.4  1.0 0.30(0, 1, 2, 3)
Values are expressed as means  standard deviation. Values of duration of AF (atrial ﬁbrillation) and LA (left atrial diameter)
are also shown as minimum to maximum value.
SR: sinus recovery, BSA: body surface area, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, Dd: Left
ventricular end-diastolic diameter, EF: Left ventricular ejection fraction, LA: Left atrial diameter
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Discussion
The present study demonstrated that 19 of 28
patients (68%) with persistent AF lasting 2 months
who failed to restore sinus rhythm after EC recov-
ered sinus rhythm after taking 100mg/day-bepridil,
16 (57%) maintained a sinus rhythm during the
follow-up period. Serious adverse events including
sudden death or torsades de pointes did not occur.
The average left atrial (LA) diameter in the study
patients was 49 7mm, and it was considered
that structural remodeling of LA occurred in these
patients. Nevertheless, bepridil, especially 100
mg/day-bepridil, was eﬀective in restoring and
maintaining the sinus rhythm in approximately half
of the patients.
Effect on converting sinus rhythm
Bepridil inhibits multiple ion channels, including
sodium, potassium (IKr, IKs, IKAch, IKur) and
Table 2 Diﬀerences in various electrocardiographic parameters between SR and AF groups
SR group (n ¼ 16) AF group (n ¼ 12) P value
Pre QRS duration (msec) 98.9  15.6 97.8  7.6 0.81
Post QRS duration (msec) 100.3  22.6 101.0  9.3 0.92
QRS duration (msec) 1.2  11.4 3.3  7.5 0.57
Pre RR interval (msec) 763.6  92.1 678.8  164.5 0.13
Post RR interval (msec) 858.4  120.2 764.3  183.2 0.15
RR interval (msec) 82.9  120.7 85.5  97.5 0.95
Pre QT interval (msec) 361.2  40.0 361.2  28.3 0.99
Post QT interval (msec) 431.5  62.4 409.3  58.2 0.35
QT interval (msec) 70.3  58.5 48.1  48.3 0.29
Pre QTc interval (msec) 423.6  31.9 448.9  27.1 0.36
Post QTc interval (msec) 448.9  42.8 452.8  23.7 0.78
QTc interval (msec) 25.3  28.1 3.8  34.9 0.08
Values are expressed as means  standard deviation.
Abbreviations are shown in text.
Before Bepridil After Bepridil (3 months)
1 mV = 10 mm
Figure 1 A representative case in SR group.
A 62 year-old-male. Before administration of bepridil, his electrocardiograms showed persistent atrial
ﬁbrillation (left panel). However, after 3 month-administration of bepridil, his electrocardiogram showed sinus
regular rhythm without any side eﬀects (right panel).
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calcium channels. In particular, bepridil prolongs the
action potential duration of the atrium by blocking
various potassium channels, and is expected to
restore and maintain the sinus rhythm in patients
with persistent AF. These eﬀects are similar to
amiodarone, which is a class III anti-arrhythmic
agent.19,20) Yoshida et al.21) reported that the main
eﬀectiveness of bepridil on preventing paroxysmal
AF was due to a class III antiarrhythmic action.
Recent reports have shown that bepridil converted
AF to sinus rhythm more frequently and maintained
sinus rhythm for longer, without extra-cardiac
complications, compared to amiodarone. Fujiki
et al.13) reported that the overall success rate for
conversion with bepridil alone or in combination
with aprindine was 69% in their study patients.
Nakazato et al.14) reported that the rate of main-
tenance of sinus rhythm with combination of bepridil
and EC was 81% during the follow-up period.
Although our study patients had previously failed EC
and had a larger LA compared with the previous
study14) and we did not use other antiarrhythmic
agents, which have been considered as negative
factors on maintaining sinus rhythm, the success rate
of conversion with bepridil in the present study was
68%, and the rate of maintenance of sinus rhythm
with bepridil was 57%. The eﬃcacy of bepridil in
our study was similar to that achieved with amio-
darone.22) Moreover, the dosage of bepridil in the
present study was lower than that of 200mg/day
commonly used in clinical practice.13,23) Therefore,
bepridil, especially when administered at a dosage
of 100mg/day, is clinically useful for maintaining
sinus rhythm.
Bepridil and adverse complications
Bepridil is very useful for AF patients, while some
previous studies have reported that bepridil provoked
life-threatening complications, such as torsades de
pointes, which can be caused by QT prolongation.
Parelman et al. reported that bepridil was related to
the development of ventricular arrhythmia and
they concluded that bepridil was unsuitable for the
treatment of AF.15) However, the dosage in their
study was 200–600mg/day, which is higher relative
to our study. On the other hand, Fujiki et al.13)
reported that bepridil at a dose of 200mg/day and
serum K  3:8mEq/L could prevent proarrhythmic
eﬀects. They also demonstrated the usefulness and
safety of bepridil. However, Yasuda et al.23) dem-
onstrated that bepridil at doses less than 200mg/day
prolonged the QT and induced torsades de points.
Nevertheless, in their study consisting of 459
patients, adverse eﬀects were observed in only 19
patients (9%), including 13 patients with prominent
QT prolongation and torsades de points in 4 patients.
Moreover, the majority of their study patients
received 200mg/day-bepridil while 50% of our
study patients received 100mg/day-bepridil. Indeed,
in SR group of our study patients, approximately
90% of the patients received 100mg bepridil.
Therefore, the absence of torsades de points events
in our study support the safety of 100mg/day-
bepridil in patients with an enlarged left atrium
and at older age, both of which are risk factors
for torsades de points.23) In our study, two adverse
events associated with bepridil occurred; one was
sinus bradycardia and the other a remarkable
prolongation of the QTc. The dosage of bepridil
in these two cases was 150 and 200mg/day,
respectively. There were no severe adverse arrhyth-
mic events, including torsades de points, in our
study.
Study limitations
In this study, there were some limitations.
First, there was no placebo control, so we could
not determine the rate of sinus recovery without
drugs (natural sinus recovery). However, a previous
study24) showed that a placebo did not induce sinus
recovery in similar patients. Our patients consisted
of patients with persistent AF who failed EC, so
natural sinus recovery is very unlikely in these
patients. Therefore, we did not use placebo control in
our study. Second, the deﬁnition of AF recurrence
depended on the 12 lead-electrocardiogram on each
visit and palpitation as the symptom. Certainly this
was a limitation as to our method. However, we
evaluated the electrocardiogram and asked all pa-
tients to report their symptoms every month in
and we tried to ﬁnd AF recurrence as much as
possible to minimize this limitation. Finally, in this
study, the AF group included both the patients who
relapsed into AF and those who had never restored to
sinus rhythm. Essentially, the former and latter
patients should be evaluated separately, however
the former group consisted of only 3 patients.
Therefore, in this study, we evaluated both groups
together as the AF group in which bepridil was not
eﬀective.
Conclusion
Bepridil, especially at a dose of 100mg/day, is
eﬀective and safe for converting to and maintaining
sinus rhythm in patients with persistent atrial
ﬁbrillation who failed to restore sinus rhythm after
EC.
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